Myeloid and Monocytic Leukemia | Pediatrics, Phase III

A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Volunteers
Health Professionals

What is the purpose of this trial?

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Shilpa Varrier

shilpa.varrier@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Stephanie Massaro, MD, MPH
Associate Professor of Pediatrics (Hematology/Oncology); Medical Director, Pediatric Hematology/Oncology; Director, Pediatric Palliative Care

Sub-Investigators

Last Updated
12/29/2023
Study HIC
#2000034938